S&P 500

5.475,09

0,27%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Lixte Biotechnology Holdings Inc (LIXTW)
Lixte Biotechnology Holdings Inc (LIXTW) Notícias

LIXTW

Lixte Biotechnology (LIXTW)

Lixte Biotechnology Holdings Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:LIXTW

1

Data	Hora	Fonte	Título	Código	Companhia
14/06/2024	15:47	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
14/06/2024	12:00	GlobeNewswire Inc.	LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
14/06/2024	10:30	GlobeNewswire Inc.	LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
06/06/2024	09:30	GlobeNewswire Inc.	Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
03/06/2024	09:30	GlobeNewswire Inc.	LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
09/05/2024	09:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
08/05/2024	10:25	GlobeNewswire Inc.	LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
24/04/2024	16:25	AllPennyStocks.com	Mixed Shelf Filing Gives Micro Cap Delayed Boost	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
27/03/2024	16:35	AllPennyStocks.com	Biotech Steals The Show Following Pre-Clinical Data Announcement	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
27/03/2024	09:30	GlobeNewswire Inc.	NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
21/03/2024	09:30	GlobeNewswire Inc.	LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
27/02/2024	10:30	GlobeNewswire Inc.	Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
26/02/2024	10:30	GlobeNewswire Inc.	LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
29/01/2024	10:30	GlobeNewswire Inc.	First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
13/11/2023	10:30	GlobeNewswire Inc.	LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
16/10/2023	09:30	GlobeNewswire Inc.	LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
09/10/2023	09:30	GlobeNewswire Inc.	LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
26/09/2023	09:30	GlobeNewswire Inc.	LIXTE Appoints Bas van der Baan as President and Chief Executive Officer	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
20/09/2023	09:30	GlobeNewswire Inc.	LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
20/07/2023	17:05	GlobeNewswire Inc.	LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
18/07/2023	09:00	GlobeNewswire Inc.	LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
17/07/2023	09:30	GlobeNewswire Inc.	Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
01/12/2020	14:30	GlobeNewswire Inc.	Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
30/11/2020	17:52	Business Wire	WestPark Capital Announces Closing of $5,700,000 Follow-On Offering & NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc....	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc